Great.-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

InvestToRetire
01-29

Great.

Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market

Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies Oze

Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":397881931735576,"tweetId":"397881931735576","gmtCreate":1738164461007,"gmtModify":1738164465143,"author":{"id":4172323236375242,"idStr":"4172323236375242","authorId":4172323236375242,"authorIdStr":"4172323236375242","name":"InvestToRetire","avatar":"https://community-static.tradeup.com/news/8d70dd9ca2f57b29c925c8b6753b8061","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Great.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Great.&nbsp;</p></body></html>","text":"Great.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/397881931735576","repostId":2507442526,"repostType":2,"repost":{"id":"2507442526","kind":"highlight","pubTimestamp":1738096888,"share":"https://www.laohu8.com/m/news/2507442526?lang=&edition=full","pubTime":"2025-01-29 04:41","market":"hk","language":"en","title":"Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2507442526","media":"GuruFocus","summary":"Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies Oze","content":"<html><body><div><div><p>Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies Ozempic as the most broadly indicated GLP-1 drug on the market. In the FLOW trial, the drug slashed the risk of severe kidney outcomes and cardiovascular-related deaths by 24%, setting the stage for a major shake-up in kidney disease treatment. With chronic kidney disease affecting 37 million U.S. adults—40% of them with diabetes—this approval unlocks a massive new market for Novo Nordisk, positioning the company for long-term dominance in cardiometabolic care.</p><p>For investors, the ripple effects go beyond Novo Nordisk's balance sheet. Last year, dialysis stocks tanked nearly 20% in a day after the trial results first dropped. Now, with FDA backing, expect more pressure on dialysis providers as Ozempic offers a compelling alternative to slow kidney disease progression. The approval also strengthens Novo Nordisk's defense against Eli Lilly (LLY, Financial), which is aggressively pushing its own GLP-1 drugs. On top of that, the company is navigating Medicare price negotiations, and this expanded indication could give it leverage in securing broader insurance coverage, a critical factor in the fight for market share.</p><p>Novo Nordisk is proving it's not just playing in the GLP-1 space—it's redefining it. Investors should keep an eye on how the company capitalizes on this momentum to widen the gap against competitors and expand its foothold in multi-use therapies. With the healthcare landscape shifting toward drugs that tackle multiple conditions in one shot, Novo Nordisk is positioning itself ahead of the curve, making this approval more than just a regulatory win—it's a strategic power move.</p></div></div></body></html>","source":"gurufocus_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ozempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOzempic's FDA Approval Just Sent Shockwaves Through the Kidney Disease Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-29 04:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.gurufocus.com/news/2670775/ozempics-fda-approval-just-sent-shockwaves-through-the-kidney-disease-market><strong>GuruFocus</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies ...</p>\n\n<a href=\"https://www.gurufocus.com/news/2670775/ozempics-fda-approval-just-sent-shockwaves-through-the-kidney-disease-market\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念"},"source_url":"https://www.gurufocus.com/news/2670775/ozempics-fda-approval-just-sent-shockwaves-through-the-kidney-disease-market","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2507442526","content_text":"Novo Nordisk (NVO, Financial) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies Ozempic as the most broadly indicated GLP-1 drug on the market. In the FLOW trial, the drug slashed the risk of severe kidney outcomes and cardiovascular-related deaths by 24%, setting the stage for a major shake-up in kidney disease treatment. With chronic kidney disease affecting 37 million U.S. adults—40% of them with diabetes—this approval unlocks a massive new market for Novo Nordisk, positioning the company for long-term dominance in cardiometabolic care.For investors, the ripple effects go beyond Novo Nordisk's balance sheet. Last year, dialysis stocks tanked nearly 20% in a day after the trial results first dropped. Now, with FDA backing, expect more pressure on dialysis providers as Ozempic offers a compelling alternative to slow kidney disease progression. The approval also strengthens Novo Nordisk's defense against Eli Lilly (LLY, Financial), which is aggressively pushing its own GLP-1 drugs. On top of that, the company is navigating Medicare price negotiations, and this expanded indication could give it leverage in securing broader insurance coverage, a critical factor in the fight for market share.Novo Nordisk is proving it's not just playing in the GLP-1 space—it's redefining it. Investors should keep an eye on how the company capitalizes on this momentum to widen the gap against competitors and expand its foothold in multi-use therapies. With the healthcare landscape shifting toward drugs that tackle multiple conditions in one shot, Novo Nordisk is positioning itself ahead of the curve, making this approval more than just a regulatory win—it's a strategic power move.","news_type":1},"isVote":1,"tweetType":1,"viewCount":7,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}